診断学の調査レビュー　2024年

Report Highlights

• The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.
• The global market for companion diagnostics is estimated to increase from $7.6 billion in 2023 and is projected to reach $15.4 billion by 2028, at a CAGR of 15.2% from 2023 through 2028.
• The global market for drugs and diagnostics for hematological disorders is expected to grow from $131.2 billion in 2024 and is projected to reach $189.3 billion by the end of 2029, at a CAGR of 7.6% during the forecast period of 2024 to 2029.

Research Review Scope

The diagnostics industry has grown despite the challenging economic conditions in recent years. The industry draws much attention and scrutiny from the public and government and is currently undergoing many changes due to increased focus on regulations. These changes can be seen across many countries. The U.S., the largest diagnostics market, is leading the trend with changes intended to make healthcare more affordable. Opportunities for the diagnostics industry are manifold with the appearance of new markets located mainly in emerging economies with varying needs.

診断業界は、近年の厳しい経済状況にもかかわらず成長してきました。業界は国民や政府から多くの注目と監視を受けており、規制への注目が高まったため、現在多くの変化が起きています。こうした変化は多くの国で見られます。最大の診断市場である米国は、ヘルスケアをより手頃な価格にすることを目的とした変化でトレンドをリードしています。主に新興経済国にさまざまなニーズを持つ新しい市場が出現し、診断業界にはさまざまな機会が生まれています。

Increasing healthcare expenditures and the growth of emerging economies have increased the demand for technologically better diagnostic devices, kits, reagents, and other accessories. Additionally, the introduction of more stringent regulations, specifically in the developed markets of the U.S. and Europe, has forced diagnostics manufacturers to launch advanced products that include new materials, a focus on in-depth indications, and the ability to produce additional new data.

医療費の増加と新興経済の成長により、より優れた技術の診断装置、キット、試薬、その他の付属品に対する需要が高まっています。さらに、特に米国とヨーロッパの先進市場では、より厳しい規制が導入されたため、診断装置メーカーは、新しい材料、詳細な適応症への重点、および追加の新しいデータを生成する機能を含む高度な製品を発売せざるを得なくなりました。

Some of the major driving factors in the market are increasing prevelance of chronic and infectious diseases, technological advancements in the diagnostics, increasing investments in AI in diagnostics market, increased applications in non-oncology areas, growing adotion of personalized medicine, and other driving factors.

Furthermore, technically sophisticated diagnostics are needed for clinical research, as the market is highly competitive, and companies must continuously reinvent their product portfolios to enter new markets and place themselves as significant players in the healthcare system. There is a shift toward a value-based healthcare market where price and purchase decisions are based on outcomes. This has further resulted in increased scrutiny of the technology of devices, and consequently, the degree of competition has risen. Some of the major players in the diagnostics market include Abbott, Medtronic, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, GE Healthcare, Koninklijke Philips N.V., Agilent Technologies Inc., QIAGEN, Danaher Corp., Sysmex, Thermo Fisher Scientific, Inc., BD, and others.

The diagnostics industry is a multi-billion-dollar market whose outlook is supposed to rise in the coming years. Hospital care is growing, and the diagnostics industry is being looked at to provide low-cost technology for home healthcare. Now, the industry seeks healthcare diagnostic devices, kits, and reagents that individuals with unskilled healthcare experience can use. The need for modern technology, equipment, and devices can be leveraged through diagnostic equipment as manufacturers seek to create better-quality healthcare solutions.

Today’s market is worthy of close investigation as it deals with the fallout from COVID-19 and how the global diagnostics market is after the post-COVID-19 pandemic. The global pandemic has impacted the diagnostics industry both positively and negatively.

The above reasons are compelling enough to analyze and research the diagnostics market, as the market has tremendous growth potential.

It includes highlights from these reports published in 2024:

2024 年に公開された以下のレポートのハイライトが含まれています。

• – BIO261A AI in Clinical and Molecular Diagnostics Market
• – BIO077F Companion Diagnostics: Technologies and Global Markets
• – PHM116C Drugs and Diagnostics for Hematological Disorders Global Markets
• – BIO233B In Vitro Diagnostics (IVD) Quality Controls: Global Market
• – HLC043H Point of Care Diagnostics: Technologies and Global Markets
• – BIO157C Polymerase Chain Reaction (PCR) for Point of Care (POC) Diagnostics
• – PHM227B Rare Disease Diagnostics: Technologies and Global Markets

After you survey the excerpts in this Research Review, we encourage you to follow up on these topics by checking out the full market research reports associated with each topic. BCC Research looks forward to serving your market intelligence needs in the future.

Table of Contents

Chapter 1 Foreword

Research Review Scope

Chapter 2 AI in Clinical and Molecular Diagnostics Market(BIO261A)

AI in Clinical and Molecular Diagnostics

Market Outlook

Scope of Report

Market Summary

Market Overview of AI in Clinical and Molecular Diagnostics

AI in Healthcare

AI in Clinical Diagnostics

AI in Molecular Diagnostics

Market Dynamics of AI in Clinical and Molecular Diagnostics

Market Drivers

Investment in the AI Health Sector

Increasing Prevalence of Chronic and Infectious Diseases

Technological Advances

Demand for Personalized Medicine

Market Restraints

Practitioners Reluctant to Adopt AI-based Technologies

Data Security

Regulatory Challenges

Market Opportunities

Software with AI

Untapped Opportunities in Developing Markets

Regulatory Structure

Emerging Technologies and Developments

Machine Learning Algorithms

Deep Learning

Generative AI

Natural Language Processing (NLP)

Genomic AI

Cloud-Based Solutions

Market Segmentation Analysis

AI in Clinical and Molecular Diagnostics: Global Markets

Molecular Diagnostics

Clinical Diagnostics

Market Analysis of AI in Clinical and Molecular Diagnostics by Component

Software

Services

Hardware

Geographic Breakdown

Market Analysis 0f AI in Clinical and Molecular Diagnostics by Region

North America

Europe

Asia-Pacific

Rest of the World

Chapter 3 Companion Diagnostics: Technologies and Markets ( BIO077F)

Companion Diagnostics

Market Outlook

Scope of Report

Market Summary

Highlights of the Market for Companion Diagnostics (CDx)

Market Introduction

Regulatory Landscape

Companion Diagnostics Regulations in the U.S.

Companion Diagnostics Regulations Outside the U.S.

LDT-CDx Regulation

Market Dynamics of Companion Diagnostics

Market Drivers

Rising Incidence of Cancer

Growing Adoption of Personalized Medicine

Expanded Application in Non-Oncology Areas

Optimization of Drug Development Costs

Market Restraints

High Development Cost of CDx

Reimbursement Challenges

Market Opportunities

Advances in NGS Technologies

Market Challenges

Inefficiencies in Clinical Testing Landscape

Lack of Skilled Labor

Emerging Technologies and Developments

Multiplex Testing

Next-Generation Sequencing (NGS)

Digital PCR

Liquid Biopsy

Artificial Intelligence

Market Segmentation Analysis

Global Market for Companion Diagnostics by Product and Service

Market Share and Forecast

Instruments

Consumables

Services

Global Market for Companion Diagnostics by Type of Test

Market Share and Forecast

LDT-CDx

Commercial CDx

Global Market for Companion Diagnostics by Technology

Market Share and Forecast

Polymerase Chain Reaction

Immunohistochemistry

Next-Generation Sequencing

In Situ Hybridization

Genotyping

Immunoassays

Exosomes

Others

Services

Global Market for Companion Diagnostics by Application

Market Share and Forecast

Cancer

Market for the Application of CDx in Cancer by Type

Neurologic Disorders

Cardiovascular Disease

Infectious Diseases

Other Diseases

Market Breakdown of Companion Diagnostics by End User

Market Share and Forecast

Clinical Laboratories

Pharmaceutical Companies

Contract Research Organizations (CROs)

Other End Users

Geographic Breakdown

Global Market for Companion Diagnostics by Region

North America

The U.S.

Canada

Europe

Germany

The U.K.

France

Italy

Rest of Europe

Asia-Pacific

China

Japan

India

Rest of Asia-Pacific

Rest of the World

Chapter 4 Drugs and Diagnostics for Hematological Disorders: Global Markets (PHM116C)

Drugs and Diagnostics for Hematological Disorders

Market Outlook

Scope of Report

Market Summary

Market Overview of Drugs and Diagnostics for Hematological Disorders

PESTEL Analysis

Political

Economic

Social

Technological

Environmental

Legal

Porter’s Five Forces Analysis

Bargaining Power of Buyers

Bargaining Power of Suppliers

Potential of New Entrants

Threat of Substitutes

Competition in the Industry

Supply Chain and Logistics for Hematological Instruments

Market Dynamics of Drugs and Diagnostics for Hematological Disorders

Market Drivers

Incidence of Blood Disorders

Rising Use of Automation

Diagnosis of Hematology Disorders

Increasing Government and Private Funding for Treatment

Market Restraints

High Cost of Instruments

High Cost of Treatment

Reimbursement Challenges for Physicians

Market Opportunities

Rising Health Awareness

Emerging Economies

Emerging Technologies and Developments

AI-Assisted Diagnosis

Next-Generation Sequencing (NGS)

Microfluidics and Lab-on-a-Chip Devices

Gene Therapies

Immunotherapies

Market Segmentation Analysis

Segmentation by Market

Hematological Disorders Diagnostics Market

Hematological Disorders Diagnostic Market, By Product Type

Hematological Disorders Diagnostic Market, By End User

Hematology Drug Market

Hematology Drug Market, By Drug Type

Geographic Breakdown

North America

Europe

Asia-Pacific

Rest of the World

Chapter 5 In Vitro Diagnostics (IVD) Quality Controls: Global Market( BIO233B)

In Vitro Diagnostics (IVD) Quality Controls

Market Outlook

Scope of Report

Market Summary

Market and Technology Background

Overview

Classification of In Vitro Diagnostics Elements

Importance of In Vitro Diagnostics Quality Control

Regulations

Regulation of IVD products in Different countries

Market Dynamics of In Vitro Diagnostics (IVD) Quality Controls

Market Drivers

Rise in the Aging Population and Dependency on Frequent Diagnosis Procedures

Rising Demand for Third-Party Quality Control Products

Rising Incidence of Chronic Disease Cases

Strengthening Clinical Laboratories

Improving the Quality of Point-of-Care Testing

Market Restraints

Challenges for Quality Control Product Packaging

Increases in Shipping Costs or Service Issues

Improper Operation and Maintenance of Laboratory Equipment and Consumables

Market Opportunities

Rise in Home Care Testing Devices

Demand for Point-of-Care (POC) Testing Units

Emerging Technologies and Developments

Artificial Intelligence

Prioritizing Old IVD Techniques

Automating In-Vitro Diagnostic Devices

Emerging Trends in In Vitro Diagnostics

FDA Approval

Rise in Demand for Personalized Medicine

Market Segmentation Analysis

Market Breakdown of In Vitro Diagnostics (IVD) Quality Controls by Test Type

Immunodiagnostics

Clinical Chemistry

Hematology

Molecular Diagnostics

Microbiology

Other Test Types

Market Breakdown of In Vitro Diagnostics (IVD) Quality Controls by Type of Manufacturer

Third-party Controls

ODM Controls

Market Breakdown of In Vitro Diagnostics (IVD) Quality Controls by Products and Services

Quality Control Products

Data Management Solutions

Quality Assurance Services

Market Breakdown of In Vitro Diagnostics (IVD) Quality Controls by End User

Diagnostic Laboratories

Hospitals and Clinics

Point-of-Care Centers

Research Institutions

Other End Users

Geographic Breakdown

Market Analysis of In Vitro Diagnostics (IVD) Quality Controls by Region

North America

Market Size and Forecast

U.S.

Canada

Mexico

Europe

Market Size and Forecast

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia-Pacific

Market Size and Forecast

Japan

China

India

Australia and New Zealand

Rest of Asia-Pacific

Rest of the World

Market Size and Forecast

Brazil

GCC Countries

Rest of the World Countries

Chapter 6 Point-of-Care Diagnostics: Technologies and Global Markets ( HLC043H)

Point-of-Care Diagnostics

Market Outlook

Scope of Report

Market Summary

Market Overview of Point-of-Care Diagnostics

Novel Approaches for POC

Significance of CLIA in the United States

Regulatory Guidelines

Good Manufacturing Practice

The FDA’s Role in POC Testing

Conclusion

Market Dynamics of Point-of-Care Diagnostics

Market Drivers

High Incidences of Infectious Diseases

Growing Prevalence of Chronic Diseases

Increasing Demand for Self-Testing

Aging Population

Market Restraints

Challenges Faced by POC Manufacturers Due to Pricing Pressure

Technical Complexity

Lack of Specialized Training

Market Challenges

Challenges in Deploying Point-of-Care (POC) Diagnostics in Remote Settings

Environmental and Contamination Challenges in Point-of-Care Diagnostics

Market Opportunities

Increasing R&D Budget

Excellent Market Potential for POCT with AI and ML Integration

Emerging Economies

Emerging and Upcoming Technologies in the Market

AI in Point-of-Care Diagnostics

CRISPR-Cas Systems

3D Rapid Prototyping

Quantum Dots

RFID (Radio-Frequency Identification) and NFC (Near Field Communication)

Smartphone-Based Medical Imaging

Nanomaterials in POC Devices for Pathogen Detection

Microfluidics-Based Sensing Technologies

Cloud-Integrated AI

D3 Array-UTI

EVIK DxSpheres: A Solid Assay Solution

UNIQO 160 Automated IIFT System

Recent Developments

Market Segmentation Analysis

Market Breakdown of Point-of-Care Diagnostics by Test Type

Drug and Alcohol Screening

Blood Gas Electrolyte and Metabolite (BGEM)

Cardiac Markers

Cholesterol Testing/Monitoring

Glucose Testing and Monitoring

Infectious Disease Testing

Pregnancy and Fertility Testing

Hemoglobin and Hemostasis

Tumor Marker

Urinalysis/Urine Chemistry

Others

Market Breakdown of Point-of-Care Diagnostics Market by Product

Hardware

Software

Market Breakdown of Point-of-Care Diagnostics Market by End User

Hospitals and Critical Care Settings

Home Care Settings

Geographic Breakdown

Market Breakdown of Point-of-Care Diagnostics Market by Region

North America

Europe

Asia-Pacific

Rest of the World (RoW)

Chapter 7 Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics (BIO157C)

Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics

Market Outlook

Scope of Report

Market Summary

Market Overview of Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics

Polymerase Chain Reaction Technology

Point of Care PCR Systems and Assays

Market Dynamics of Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics

Market Drivers

Increasing Incidence of Infectious Diseases

Decentralization of Testing

Increasing Adoption of Point-of-Care Testing and Expansion

Multiplexing Testing

Response to the Pandemics

Market Opportunities

Integration of PCR POC Technology in Primary Care and Low-Income Countries

Market Restraints

High Initial Cost

Market Competition

Market Challenges

Operational Challenges

Supply Shortages

Emerging Technologies and Developments

Instrument-Free PCR Tests

Five-Minute Point-of-Care Testing

Smartphone Enabled PCR System

Global Market for PCR POC Diagnostics

Market Breakdown of Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics by Product Type

Market Breakdown of Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics by Analyte

PCR POC Analyzers by Analyte

PCR POC Consumables by Analyte

Market Breakdown of Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics by Application

Infectious Diseases

STIs

Geographic Breakdown

Market Breakdown of Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics by Region

North America

Latin America

Europe

Asia-Pacific

Rest of the World

Chapter 8 Rare Disease Diagnostics: Technologies and Global Markets (PHM227B)

Rare Disease Diagnostics

Market Outlook

Scope of Report

Market Summary

Market Overview of Rare Disease Diagnostics

Diagnostic Odyssey

What Is Genomic Testing?

Rare Disease Clinical Assays Development and Marketing

Rare Disease Treatment

Bioinformatic Resources for Rare Disease Research and Genetic Information

Large-Scale Initiatives and Consortia

Population Sequencing Programs

Market Dynamics of Rare Disease Diagnostics

Market Drivers

Significant Unmet Need in Rare Disease Diagnostics

Orphan Drug Act

Advances In Gene Therapy

Rare Disease Initiatives

Advances in Genomic Technologies and Analytical Tools

Decreasing Cost of Next-Generation Sequencing (NGS)

Market Driving Forces and Their Impact on Market Growth

Market Restraints

Lack of Commercially Available IVDs for Rare Disease Diagnosis

Stringent Regulatory Landscape

Ethical and Legal Concerns

Shortage of Genetic and Rare Disease Specialists

Emerging Technologies and Developments

Shift Towards a Multi-omics Approach

Artificial Intelligence (AI) and Machine Learning

Collaboration Between Rare Disease Diagnostics and Pharma Companies

Market Segmentation Analysis

Market Breakdown of Rare Disease Diagnostics by Analysis Platform

Next-Generation Sequencing (NGS)

Polymerase Chain Reaction (PCR)

Sanger Sequencing

Microarrays

Karyotyping and Fluorescent in Situ Hybridization (FISH)

Biochemical Testing

Market Breakdown of Rare Disease Diagnostics by Analysis Target Type

Single Genes

Multiple Genes

Whole Exome

Whole Genome

Other Genomic Variants

Protein and Other Biochemical Markers

Market Breakdown of Rare Disease Diagnostics by Disease Class

Rare Cancers

Neurological Diseases

Metabolic and Endocrine Disorders

Hematology

Respiratory

Immune System and Inflammation-Related Disorders

Dermatology

Musculoskeletal

Others

Market Breakdown of Rare Disease Diagnostics by Test Purpose

Diagnosis

Screening and Early Detection

Therapy Guidance

Monitoring

Geographic Breakdown

Market Breakdown of Rare Disease Diagnostics by Region

North America

Europe

Asia-Pacific

Rest of the World

Chapter 9 Appendix

Methodology

Analyst’s Credentials

List of Tables

Table 1 : Global Market for AI in Clinical and Molecular Diagnostics, by Type, Through 2029

Table 2 : Global Market for AI in Clinical and Molecular Diagnostics, by Region, Through 2029

Table 3 : Regulations Pertaining to AI Medical Diagnostics

Table 4 : Global Market for AI in Clinical and Molecular Diagnostics, Through 2029

Table 5 : Global Market for AI in Clinical and Molecular Diagnostics, by Type, Through 2029

Table 6 : Global Market for AI in Molecular Diagnostics, by Application, Through 2029

Table 7 : Incidence of Cancer, by Region, 2022

Table 8 : Number of DALYs for Neurological Disorders and Share of Global DALYs Projected for 2005 and 2030

Table 9 : Global Market for AI in Molecular Diagnostics, by Product Type, Through 2029

Table 10 : Global Market for AI in Clinical Diagnostics, by Test, Through 2029

Table 11 : Global Market for AI in Clinical Diagnostics, by Product, Through 2029

Table 12 : Global Market for AI in Clinical and Molecular Diagnostics, by Component, Through 2029

Table 13 : Global Market for AI in Clinical and Molecular Diagnostics, by Region, Through 2029

Table 14 : North American Market for AI in Clinical and Molecular Diagnostics, by Country, Through 2029

Table 15 : European Market for AI in Clinical and Molecular Diagnostics, by Country, Through 2029

Table 16 : Asia-Pacific Market for AI in Clinical and Molecular Diagnostics, by Country, Through 2029

Table 17 : RoW Market for AI in Clinical and Molecular Diagnostics, by Sub-Region, Through 2029

Table 18 : Global Market for Companion Diagnostics, by Product, Through 2028

Table 19 : Global Market for Companion Diagnostics, by Region, Through 2028

Table 20 : Expanded/New CDx Testing for Personalized Medicine in 2022

Table 21 : Global Market for Companion Diagnostics, by Product and Service, Through 2028

Table 22 : Companion Diagnostics Instruments

Table 23 : Global Market for Companion Diagnostics Instruments, by Region, Through 2028

Table 24 : Global Market for Companion Diagnostics Consumables, by Region, Through 2028

Table 25 : Global Market for Companion Diagnostics Services, by Region, Through 2028

Table 26 : Global Market for Companion Diagnostics, by Type of Test, Through 2028

Table 27 : Global Market for Laboratory Developed Test (LDT)-CDx, by Region, Through 2028

Table 28 : List of FDA-Approved Companion Diagnostics, by Company, as of December 2023

Table 29 : Global Market for Commercial-CDx, by Region, Through 2028

Table 30 : FDA-Approved CDx Tests, by Technology, as of December 2023

Table 31 : Global Market for Companion Diagnostics, by Technology, Through 2028

Table 32 : List of FDA-Approved PCR-CDx, by Company, as of December 2023

Table 33 : Global Market for Polymerase Chain Reaction CDx, by Region, Through 2028

Table 34 : Global Market for Polymerase Chain Reaction CDx, by Application, Through 2028

Table 35 : List of FDA-Approved IHC-CDx, by Company, as of December 2023

Table 36 : Global Market for Immunohistochemistry CDx, by Region, Through 2028

Table 37 : Global Market for Immunohistochemistry CDx, by Application, Through 2028

Table 38 : List of FDA-Approved NGS-CDx, by Company, as of December 2023

Table 39 : Global Market for Next-Generation Sequencing CDx, by Region, Through 2028

Table 40 : Global Market for Next-Generation Sequencing CDx, by Application, Through 2028

Table 41 : Global Market for In Situ Hybridization CDx, by Region, Through 2028

Table 42 : Global Market for In Situ Hybridization CDx, by Application, Through 2028

Table 43 : Global Market for Genotyping CDx, by Region, Through 2028

Table 44 : Global Market for Genotyping CDx, by Application, Through 2028

Table 45 : Global Market for Immunoassays CDx, by Region, Through 2028

Table 46 : Global Market for Immunoassays CDx, by Application, Through 2028

Table 47 : Global Market for Exosome CDx, by Region, Through 2028

Table 48 : Global Market for Exosomes CDx, by Application, Through 2028

Table 49 : Global Market for Other CDx, by Region, Through 2028

Table 50 : Global Market for Other CDx, by Application, Through 2028

Table 51 : Technological Expertise in the CDx Services Sector

Table 52 : Global Market for CDx Services, by Region, Through 2028

Table 53 : Global Market for CDx Services, by Application, Through 2028

Table 54 : Global Market for Companion Diagnostics, by Application, Through 2028

Table 55 : Global Market for Companion Diagnostics in Cancer Applications, by Region, Through 2028

Table 56 : Cancer Incidence, Global, by Cancer Type, 2022

Table 57 : Approved CDx Drugs for Cancer Treatment, by Cancer Type, 2023

Table 58 : Global Market for Companion Diagnostics in Cancer Applications, by Cancer Type, Through 2028

Table 59 : Global Market for Companion Diagnostics in Neurologic Disorder Applications, by Region, Through 2028

Table 60 : Global Market for Companion Diagnostics in Neurologic Disorder Applications, by Type, Through 2028

Table 61 : Global Market for Companion Diagnostics in Cardiovascular Disease Applications, by Region, Through 2028

Table 62 : Global Market for Companion Diagnostics in Infectious Disease Applications, by Region, Through 2028

Table 63 : Global Market for Companion Diagnostics in Other Disease Applications, by Region, Through 2028

Table 64 : Global Market for Companion Diagnostics, by End User, Through 2028

Table 65 : Global Market for Companion Diagnostics in Clinical Laboratories, by Region, Through 2028

Table 66 : Recent Collaborations and Partnerships in the Companion Diagnostics Market, 2022 and 2023

Table 67 : Global Market for Companion Diagnostics in Pharmaceutical Companies, by Region, Through 2028

Table 68 : Global Market for Companion Diagnostics in Contract Research Organizations, by Region, Through 2028

Table 69 : Global Market for Companion Diagnostics in Other End Users, by Region, Through 2028

Table 70 : Global Market for Companion Diagnostics, by Region, Through 2028

Table 71 : North American Market for Companion Diagnostics, by Country, Through 2028

Table 72 : European Market for Companion Diagnostics, by Country, Through 2028

Table 73 : Asia-Pacific Market for Companion Diagnostics, by Country, Through 2028

Table 74 : Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, Through 2029

Table 75 : Blood-Related Disorders

Table 76 : Incidence of Blood Cancer Types in U.S., 2023

Table 77 : Total Cost of Care for CLL Patients Treated in the U.S., 2023

Table 78 : Global Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029

Table 79 : Global Market for Diagnostics for Hematological Disorders, by Region, Through 2029

Table 80 : Global Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029

Table 81 : Global Market for Hematology Instruments and Software, by Region, Through 2029

Table 82 : Global Market for Hematology Reagents, by Region, Through 2029

Table 83 : Global Market for Diagnostics for Hematological Disorders, by End User, Through 2029

Table 84 : Global Market for Hematology Diagnosis in Diagnostic Centers, by Region, Through 2029

Table 85 : Global Market for Hematology Diagnosis in Hospitals and Clinics, by Region, Through 2029

Table 86 : Global Market for Hematology Diagnosis in Other End Users, by Region, Through 2029

Table 87 : Global Market for Hematology Drugs, by Region, Through 2029

Table 88 : Global Market for Hematology Drugs, by Drug Type, Through 2029

Table 89 : Drugs Approved for Hematologic Cancers

Table 90 : Global Market for Hematology Oncology Drugs, by Region, Through 2029

Table 91 : Global Market for Hematology Non-Oncology Drugs, by Region, Through 2029

Table 92 : Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, Through 2029

Table 93 : North American Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029

Table 94 : North American Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029

Table 95 : North American Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029

Table 96 : North American Market for Diagnostics for Hematological Disorders, by End User, Through 2029

Table 97 : North American Market for Hematology Drugs, by Drug Type, Through 2029

Table 98 : European Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029

Table 99 : European Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029

Table 100 : European Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029

Table 101 : European Market for Diagnostics for Hematological Disorders, by End User, Through 2029

Table 102 : European Market for Hematology Drugs, by Drug Type, Through 2029

Table 103 : Incidence of Blood-Related Cancers, by Country, 2022

Table 104 : Asia-Pacific Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029

Table 105 : Asia-Pacific Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029

Table 106 : Asia-Pacific Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029

Table 107 : Asia-Pacific Market for Diagnostics for Hematological Disorders, by End User, Through 2029

Table 108 : Asia-Pacific Market for Hematology Drugs, by Drug Type, Through 2029

Table 109 : Asia-Pacific Incidence of Blood-Related Cancers, by Country, 2022

Table 110 : RoW Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029

Table 111 : RoW Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029

Table 112 : RoW Market for Diagnostics for Hematological Disorders, by End User, Through 2029

Table 113 : RoW Market for Hematology Drugs, by Drug Type, Through 2029

Table 114 : Global Market for In Vitro Diagnostics Quality Controls, by Test Type, Through 2029

Table 115 : Global Market for In Vitro Diagnostics Quality Controls, by Test Type, Through 2029

Table 116 : Global Market for Immunodiagnostics, by Region, Through 2029

Table 117 : Global Market for Clinical Chemistry, by Region, Through 2029

Table 118 : Global Market for Hematology, by Region, Through 2029

Table 119 : Global Market for Molecular Diagnostics, by Region, Through 2029

Table 120 : Global Market for Microbiology, by Region, Through 2029

Table 121 : Global Market for Other Test Types, by Region, Through 2029

Table 122 : Global Market for In Vitro Diagnostics Quality Controls, by Type of Manufacturer, Through 2029

Table 123 : Global Market for Third-party Controls, by Region, Through 2029

Table 124 : Global Market for ODM Controls, by Region, Through 2029

Table 125 : Global Market for In Vitro Diagnostics Quality Controls, by Type of Product and Service, Through 2029

Table 126 : Global Market for Quality Control Products, by Region, Through 2029

Table 127 : Global Market for Serum/Plasma-Based Controls, by Region, Through 2029

Table 128 : Global Market for Whole Blood-Based Controls, by Region, Through 2029

Table 129 : Global Market for Urine-based Controls, by Region, Through 2029

Table 130 : Global Market for Other Quality Control Products, by Region, Through 2029

Table 131 : Global Market for Data Management Solutions, by Region, Through 2029

Table 132 : Global Market for Quality Assurance Services, by Region, Through 2029

Table 133 : Global Market for In Vitro Diagnostics Quality Controls, by End User, Through 2029

Table 134 : Global Market for IVD Quality Controls in Diagnostic Laboratories, by Region, Through 2029

Table 135 : Global Market for IVD Quality Controls in Hospitals and Clinics, by Region, Through 2029

Table 136 : Global Market for IVD Quality Controls in Point-of-Care Centers, by Region, Through 2029

Table 137 : Global Market for IVD Quality Controls in Research Institutions, by Region, Through 2029

Table 138 : Global Market for Other End Users, by Region, Through 2029

Table 139 : Global Market for In Vitro Diagnostics Quality Controls, by Region, Through 2029

Table 140 : North American Market for In Vitro Diagnostics Quality Controls, by Country, Through 2029

Table 141 : European Market for In Vitro Diagnostics Quality Controls, by Country, Through 2029

Table 142 : Asia-Pacific Market for In Vitro Diagnostics Quality Controls, by Country, Through 2029

Table 143 : Rest of the World Market for In Vitro Diagnostics Quality Controls, by Country/Sub-Region, Through 2029

Table 144 : Global Market for Point-of-Care Diagnostics, by Region, Through 2029

Table 145 : POCT Alternatative Terms

Table 146 : Commonly Used POC Devices

Table 147 : Recent Tests Approved by the FDA as Waived Tests Under CLIA

Table 148 : Estimated Number of People Living with HIV, 2010, 2021 and 2022

Table 149 : Number of Hepatitis B Infections (All Ages) in 2022

Table 150 : Global Incidences of STIs, 2020 and 2022

Table 151 : Projected Number of Adults 50 Years and Older with ≥1 Chronic Condition in the United States, 2020–2050

Table 152 : Number and Proportion of Persons Aged 65 Years and Over, by Development Group, 2023 and 2050

Table 153 : Number of Persons Aged 65 Years and Over, by Region, 2019 and 2050

Table 154 : Number of Deaths and the Age-Adjusted Death Rate for the 10 Leading Causes of Death in 2022: United States, 2021 and 2022

Table 155 : Global Market for Point-of-Care Diagnostics, by Test Type, Through 2029

Table 156 : Global Market for Drug and Alcohol Screening, by Region, Through 2029

Table 157 : Global Market for BGEM, by Region, Through 2029

Table 158 : Global Market for Cardiac Markers, by Region, Through 2029

Table 159 : Global Market for Cholesterol Testing/Monitoring, by Region, Through 2029

Table 160 : Global Market for Glucose Testing and Monitoring, by Region, Through 2029

Table 161 : Annual Estimated Deaths from HIV/AIDS, Diarrhea, Malaria, Respiratory Infections, and All Other Infectious Diseases in Major Countries, 1980 to 2021

Table 162 : Global Market for Infectious Disease Testing, by Region, Through 2029

Table 163 : Global Market for Pregnancy and Fertility Testing, by Region, Through 2029

Table 164 : Global Market for Hemoglobin and Hemostasis, by Region, Through 2029

Table 165 : Examples of Commercially Available POC Devices for Cancer Detection

Table 166 : Global Market for Tumor Markers, by Region, Through 2029

Table 167 : Some Currently Available Point-of-Care Tests for Proteins in Urine

Table 168 : Global Market for Urinalysis/Urine Chemistry, by Region, Through 2029

Table 169 : Global Market for Other Types of Point-of-Care Diagnostics Tests, by Region, Through 2029

Table 170 : Global Market for Point-of-Care Diagnostics, by Product, Through 2029

Table 171 : Global Market for Hardware in Point-of-Care Diagnostics, by Region, Through 2029

Table 172 : Global Market for Software in Point-of-Care Diagnostics, by Region, Through 2029

Table 173 : Global Market for Point-of-Care Diagnostics, by End User, Through 2029

Table 174 : Global Market for Point-of-Care Diagnostics in Hospital and Critical Care End Uses, by Region, Through 2029

Table 175 : Global Market for Point-of-Care Diagnostics in Home Care Settings, by Region, Through 2029

Table 176 : Global Market for Point-of-Care Diagnostics, by Region, Through 2029

Table 177 : North American Market for Point-of-Care Diagnostics, by Test Type, Through 2029

Table 178 : North American Market for Point-of-Care Diagnostics, by Product, Through 2029

Table 179 : North American Market for Point-of-Care Diagnostics, by End User, Through 2029

Table 180 : North American Market for Point-of-Care Diagnostics, by Country, Through 2029

Table 181 : U.S. Market for Point-of-Care Diagnostics, by Test Type, Through 2029

Table 182 : U.S. Market for Point-of-Care Diagnostics, by Product, Through 2029

Table 183 : U.S. Market for Point-of-Care Diagnostics, by End User, Through 2029

Table 184 : Canadian Market for Point-of-Care Diagnostics, by Test Type, Through 2029

Table 185 : Canadian Market for Point-of-Care Diagnostics, by Product, Through 2029

Table 186 : Canadian Market for Point-of-Care Diagnostics, by End User, Through 2029

Table 187 : Mexican Market for Point-of-Care Diagnostics, by Test Type, Through 2029

Table 188 : Mexican Market for Point-of-Care Diagnostics, by Product, Through 2029

Table 189 : Mexican Market for Point-of-Care Diagnostics, by End User, Through 2029

Table 190 : European Market for Point-of-Care Diagnostics, by Test Type, Through 2029

Table 191 : European Market for Point-of-Care Diagnostics, by Product, Through 2029

Table 192 : European Market for Point-of-Care Diagnostics, by End User, Through 2029

Table 193 : European Market for Point-of-Care Diagnostics, by Country, Through 2029

Table 194 : Leading Causes of Disease Burden by DALYs (Level 3)

Table 195 : German Market for Point-of-Care Diagnostics, by Test Type, Through 2029

Table 196 : German Market for Point-of-Care Diagnostics, by Product, Through 2029

Table 197 : German Market for Point-of-Care Diagnostics, by End User, Through 2029

Table 198 : U.K. Market for Point-of-Care Diagnostics, by Test Type, Through 2029

Table 199 : U.K. Market for Point-of-Care Diagnostics, by Product, Through 2029

Table 200 : U.K. Market for Point-of-Care Diagnostics, by End User, Through 2029

Table 201 : French Market for Point-of-Care Diagnostics, by Test Type, Through 2029

Table 202 : French Market for Point-of-Care Diagnostics, by Product, Through 2029

Table 203 : French Market for Point-of-Care Diagnostics, by End User, Through 2029

Table 204 : Italian Market for Point-of-Care Diagnostics, by Test Type, Through 2029

Table 205 : Italian Market for Point-of-Care Diagnostics, by Product, Through 2029

Table 206 : Italian Market for Point-of-Care Diagnostics, by End User, Through 2029

Table 207 : Spanish Market for Point-of-Care Diagnostics, by Test Type, Through 2029

Table 208 : Spanish Market for Point-of-Care Diagnostics, by Product, Through 2029

Table 209 : Spanish Market for Point-of-Care Diagnostics, by End User, Through 2029

Table 210 : Rest of European Market for Point-of-Care Diagnostics, by Test Type, Through 2029

Table 211 : Rest of European Market for Point-of-Care Diagnostics, by Product, Through 2029

Table 212 : Rest of European Market for Point-of-Care Diagnostics, by End User, Through 2029

Table 213 : Asia-Pacific Market for Point-of-Care Diagnostics, by Test Type, Through 2029

Table 214 : Asia-Pacific Market for Point-of-Care Diagnostics, by Product, Through 2029

Table 215 : Asia-Pacific Market for Point-of-Care Diagnostics, by End User Through 2029

Table 216 : Asia-Pacific Market for Point-of-Care Diagnostics, by Country, Through 2029

Table 217 : Chinese Market for Point-of-Care Diagnostics, by Test Type, Through 2029

Table 218 : Chinese Market for Point-of-Care Diagnostics, by Product, Through 2029Chinese Market for Point-of-Care Diagnostics, by Product, Through 2029

Table 219 : Chinese Market for Point-of-Care Diagnostics, by End User, Through 2029

Table 220 : Japanese Market for Point-of-Care Diagnostics, by Test Type, Through 2029

Table 221 : Japanese Market for Point-of-Care Diagnostics, by Product, Through 2029

Table 222 : Japanese Market for Point-of-Care Diagnostics, by End User, Through 2029

Table 223 : Indian Market for Point-of-Care Diagnostics, by Test Type, Through 2029

Table 224 : Indian Market for Point-of-Care Diagnostics, by Product, Through 2029

Table 225 : Indian Market for Point-of-Care Diagnostics, by End User, Through 2029

Table 226 : Australian Market for Point-of-Care Diagnostics, by Test Type, Through 2029

Table 227 : Australian Market for Point-of-Care Diagnostics, by Product, Through 2029

Table 228 : Australian Market for Point-of-Care Diagnostics, by End User, Through 2029

Table 229 : South Korean Market for Point-of-Care Diagnostics, by Test Type, Through 2029

Table 230 : South Korean Market for Point-of-Care Diagnostics, by Product, Through 2029

Table 231 : South Korean Market for Point-of-Care Diagnostics, by End User, Through 2029

Table 232 : Rest of Asia-Pacific Market for Point-of-Care Diagnostics, by Test Type, Through 2029

Table 233 : Rest of Asia-Pacific Market for Point-of-Care Diagnostics, by Product, Through 2029

Table 234 : Rest of Asia-Pacific Market for Point-of-Care Diagnostics, by End User, Through 2029

Table 235 : Rest of the World Market for Point-of-Care Diagnostics, by Test Type, Through 2029

Table 236 : Rest of the World Market for Point-of-Care Diagnostics, by Product, Through 2029

Table 237 : Rest of the World Market for Point-of-Care Diagnostics, by End User, Through 2029

Table 238 : Global Market for Polymerase Chain Reaction for Point-of-Care Diagnostics, by Product Type, Through 2029

Table 239 : Global HIV Infections, 2022

Table 240 : People Living with HIV, by Region, 2022

Table 241 : Global Incidence of All Cancers, by Region, 2022–2050

Table 242 : Global Incidence of Leukemia, by Region, 2022–2050

Table 243 : Global Incidence of Hodgkin Lymphoma, by Region, 2022–2050

Table 244 : Global Incidence of Non-Hodgkin Lymphoma, by Region, 2022–2050

Table 245 : Global Incidence of Multiple Myeloma, by Region, 2022–2050

Table 246 : Global Market for PCR POC Diagnostics, Through 2029

Table 247 : Global Market for PCR POC Diagnostics, by Product Type, Through 2029

Table 248 : Global Market for PCR POC Analyzers, by Analyte, Through 2029

Table 249 : Global Market for Single Analyte PCR POC Analyzers, by Region, Through 2029

Table 250 : Global Market for Multi-Analyte PCR POC Analyzers, by Region, Through 2029

Table 251 : Global Market for PCR POC Consumables, by Analyte, Through 2029

Table 252 : Global Market for Single Analyte PCR POC Consumables, by Region, Through 2029

Table 253 : Global Market for Multi-Analyte PCR POC Consumables, by Region, Through 2029

Table 254 : Global Market for PCR for POC Diagnostics, by Application, Through 2029

Table 255 : Global Market for PCR POC Diagnostics in Infectious Diseases, Through 2029

Table 256 : Global Market for PCR POC Diagnostics in Infectious Diseases, by Region, Through 2029

Table 257 : North American Market for PCR POC Diagnostics in Infectious Diseases, Through 2029

Table 258 : North American Market for PCR POC Diagnostics in Infectious Diseases, by Country, Through 2029

Table 259 : Latin American Market for PCR POC Diagnostics in Infectious Diseases, Through 2029

Table 260 : Latin American Market for PCR POC Diagnostics in Infectious Diseases, by Country, Through 2029

Table 261 : European Market for PCR POC Diagnostics in Infectious Diseases, Through 2029

Table 262 : European Market for PCR POC Diagnostics in Infectious Diseases, by Country, Through 2029

Table 263 : Asia-Pacific Market for PCR POC Diagnostics in Infectious Diseases, Through 2029

Table 264 : Asia-Pacific Market for PCR POC Diagnostics in Infectious Diseases, by Country, Through 2029

Table 265 : RoW Market for PCR POC Diagnostics in Infectious Diseases, Through 2029

Table 266 : Global Market for PCR POC Diagnostics in STIs, Through 2029

Table 267 : Global Market for PCR POC Diagnostics in STIs, by Region, Through 2029

Table 268 : North American Market for PCR POC Diagnostics in STIs, Through 2029

Table 269 : North American Market for PCR POC Diagnostics in STIs, by Country, Through 2029

Table 270 : Latin American Market for PCR POC Diagnostics in STIs, Through 2029

Table 271 : Latin American Market for PCR POC Diagnostics in STIs, by Country, Through 2029

Table 272 : European Market for PCR POC Diagnostics in STIs, Through 2029

Table 273 : European Market for PCR POC Diagnostics in STIs, by Country, Through 2029

Table 274 : Asia-Pacific Market for PCR POC Diagnostics in STIs, Through 2029

Table 275 : Asia-Pacific Market for PCR POC Diagnostics in STIs, by Country, Through 2029

Table 276 : RoW Market for PCR POC Diagnostics in STIs, Through 2029

Table 277 : Global Market for PCR for POC Diagnostics, by Region, Through 2029

Table 278 : North American Market for PCR POC Diagnostics, by Product Type, Through 2029

Table 279 : North American Market for PCR POC Diagnostics, by Country, Through 2029

Table 280 : Latin American Market for PCR POC Diagnostics, by Product Type, Through 2029

Table 281 : Latin American Market for PCR POC Diagnostics, by Country, Through 2029

Table 282 : European Market for PCR POC Diagnostics, by Product Type, Through 2029

Table 283 : European Market for PCR POC Diagnostics, by Country, Through 2029

Table 284 : Asia-Pacific Market for PCR POC Diagnostics, by Product Type, Through 2029

Table 285 : Asia-Pacific Market for PCR POC Diagnostics, by Country, Through 2029

Table 286 : RoW Market for PCR POC Diagnostics, by Product Type, Through 2029

Table 287 : Global Market for Rare Disease Diagnostics, by Disease Class, Through 2029

Table 288 : Rare Disease Prevalence Definitions

Table 289 : Statistics for Rare Diseases

Table 290 : Most Prevalent Rare Diseases

Table 291 : Examples of Genomic Biomarkers

Table 292 : Rare Disease Diagnostics Key Genetic Analysis Platforms

Table 293 : Genome Coverage of PCR, Microarray and NGS Technology Platforms

Table 294 : NGS vs. qPCR vs. Microarrays: A Detailed Comparison

Table 295 : Multiple Paths to Market for Rare Disease Tests

Table 296 : Bioinformatic Resources for Rare Disease Research and Genetic Information

Table 297 : Impact of Large-Scale Initiatives on the Rare Disease Diagnostic Industry

Table 298 : Key Rare Disease Initiatives

Table 299 : Population Sequencing Projects

Table 300 : Pathways for Accelerated Approval of Rare Disease Therapies, by Country/Region

Table 301 : Genetic Modification Approaches for Rare Diseases

Table 302 : Distinct Features of the Genetic Modification Approaches

Table 303 : Comparison of Clinical Genomic Testing Methods for Analysis of Genomic Variants

Table 304 : Driving Forces and Their Impact on Rare Disease Diagnostic Market Growth

Table 305 : Rare Disease Diagnostics Artificial Intelligence Industry

Table 306 : Global Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029

Table 307 : NGS Applications in Rare Diseases

Table 308 : Key Forces Driving Growth in Clinical NGS and Their Implications

Table 309 : Main Ingredients for Polymerase Chain Reaction

Table 310 : Polymerase Chain Reaction Process Steps

Table 311 : Sanger Sequencing Summary

Table 312 : Sanger Sequencing Improvements

Table 313 : Molecular Genetic Testing Methods

Table 314 : Cytogenetics Testing Methods

Table 315 : Biochemical Genetics Methods

Table 316 : Global Market for Rare Disease Diagnostics, by Analysis Target, Through 2029

Table 317 : Single-Gene Disorders

Table 318 : Comparison of Techniques Employed to Study Rare Genetic Diseases

Table 319 : Comparison of Genomic Methods for Rare Disease Diagnosis

Table 320 : Global Market for Rare Disease Diagnostics, by Disease Class, Through 2029

Table 321 : Rare Cancer-Focused Initiatives and Consortia

Table 322 : Selected Rare Cancer Prevalence, 2022

Table 323 : Global Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

Table 324 : Preventive Genetic Screening Tests

Table 325 : Global Market for Rare Disease Diagnostics, by Region, Through 2029

Table 326 : NIH Funding, 2018–FY2025

Table 327 : Key FDA Programs to Support Rare Disease Research

Table 328 : North American Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029

Table 329 : North American Market for Rare Disease Diagnostics, by Analysis Target, Through 2029

Table 330 : North American Market for Rare Disease Diagnostics, by Disease Class, Through 2029

Table 331 : North American Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

Table 332 : North American Market for Rare Disease Diagnostics, by Country, Through 2029

Table 333 : U.S. Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029

Table 334 : U.S. Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

Table 335 : Canadian Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029

Table 336 : Canadian Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

Table 337 : Mexican Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029

Table 338 : Mexican Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

Table 339 : Overview of Actions Taken by the EU to Address Challenges in the Field of Rare Diseases Diagnosis

Table 340 : European Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029

Table 341 : European Market for Rare Disease Diagnostics, by Analysis Target, Through 2029

Table 342 : European Market for Rare Disease Diagnostics, by Disease Class, Through 2029

Table 343 : European Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

Table 344 : European Market for Rare Disease Diagnostics, by Country, Through 2029

Table 345 : German Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029

Table 346 : German Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

Table 347 : U.K. Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029

Table 348 : U.K. Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

Table 349 : French Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029

Table 350 : French Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

Table 351 : Italian Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029

Table 352 : Italian Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

Table 353 : Spanish Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029

Table 354 : Spanish Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

Table 355 : Rest of European Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029

Table 356 : Rest of European Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

Table 357 : Asia-Pacific Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029

Table 358 : Asia-Pacific Market for Rare Disease Diagnostics, by Analysis Target, Through 2029

Table 359 : Asia-Pacific Market for Rare Disease Diagnostics, by Disease Class, Through 2029

Table 360 : Asia-Pacific Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

Table 361 : Asia-Pacific Market for Rare Disease Diagnostics, by Country, Through 2029

Table 362 : Chinese Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029

Table 363 : Chinese Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

Table 364 : Japanese Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029

Table 365 : Japanese Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

Table 366 : Australian Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029

Table 367 : Australian Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

Table 368 : South Korean Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029

Table 369 : South Korean Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

Table 370 : Rest of Asia-Pacific Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029

Table 371 : Rest of Asia-Pacific Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

Table 372 : RoW Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029

Table 373 : RoW Market for Rare Disease Diagnostics, by Analysis Target, Through 2029

Table 374 : RoW Market for Rare Disease Diagnostics, by Disease Class, Through 2029

Table 375 : RoW Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

List of Figures

Figure 1 : Market Dynamics of AI in Clinical and Molecular Diagnostics

Figure 2 : Global Market Shares of AI in Clinical and Molecular Diagnostics, by Type, 2023

Figure 3 : Global Market Shares of AI in Molecular Diagnostics, by Application, 2023

Figure 4 : Global Deaths from Cancer, 2015 and 2030

Figure 5 : Global Market Shares of AI in Molecular Diagnostics, by Product Type, 2023

Figure 6 : Global Market Shares of AI in Clinical Diagnostics, by Test, 2023

Figure 7 : Global Market Shares of AI in Clinical Diagnostics, by Product, 2023

Figure 8 : Global Market Shares of AI in Clinical and Molecular Diagnostics, by Component, 2023

Figure 9 : Global Market Shares of AI in Clinical and Molecular Diagnostics, by Region, 2023

Figure 10 : North American Market Shares of AI in Clinical and Molecular Diagnostics, by Country, 2023

Figure 11 : European Market Shares of AI in Clinical and Molecular Diagnostics, by Country, 2023

Figure 12 : Asia-Pacific Market Shares of AI in Clinical and Molecular Diagnostics, by Country, 2023

Figure 13 : RoW Market Shares of AI in Clinical and Molecular Diagnostics, by Sub-Region, 2023

Figure 14 : Timeline of FDA Guidance Release for Companion Diagnostics (CDx), as of 2023

Figure 15 : Market Dynamics of Companion Diagnostics

Figure 16 : Share of Global Cancer Incidence for Both Sexes, by Region, 2022

Figure 17 : Companion Diagnostics: Growing Share in Total New Molecular Entities (NMEs), 2019–2022

Figure 18 : Emerging Trends/Technologies in the Companion Diagnostics Market

Figure 19 : Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, 2021-2029

Figure 20 : Market Dynamics of Drugs and Diagnostics for Hematological Disorders

Figure 21 : Incidence of Blood Cancer Types, by Region, 2022

Figure 22 : Global Market Shares of Drugs and Diagnostics for Hematological Disorders, by Segment, 2023

Figure 23 : Global Market Shares of Diagnostics for Hematological Disorders, by Product Type, 2023

Figure 24 : Global Market Shares of Diagnostics for Hematological Disorders, by End User, 2023

Figure 25 : Global Market Shares of Hematology Drugs, by Drug Type, 2023

Figure 26 : North American Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023

Figure 27 : New Cases of Leukemia, Lymphoma and Myeloma in U.S., 2023

Figure 28 : European Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023

Figure 29 : Asia-Pacific Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023

Figure 30 : Global Market Shares of In Vitro Diagnostics Quality Controls, by Test Type, 2023

Figure 31 : In Vitro Diagnostics (IVD) Quality Controls Global Market: Market Dynamics

Figure 32 : Distribution of Elderly Population (Aged 65 and above), by Top Countries, 2022

Figure 33 : Comparison Between Third-Party Controls and Original Equipment Manufacturer Controls

Figure 34 : Global Market Shares of In Vitro Diagnostics Quality Controls, by Test Type 2023

Figure 35 : Global Market Shares of In Vitro Diagnostics Quality Control, by Type of Manufacturer 2023

Figure 36 : Global Market Shares of In Vitro Diagnostics Quality Controls, by Type of Product and Service, 2023

Figure 37 : Global Market Shares of In Vitro Diagnostics Quality Controls, by Type of Quality Control Product, 2023

Figure 38 : Global Market Shares of In Vitro Diagnostics Quality Controls, by End-user, 2023

Figure 39 : Global Market Shares of In Vitro Diagnostics Quality Controls, by Region, 2023

Figure 40 : North American Market Shares of In Vitro Diagnostics Quality Controls, by Test Type, 2023

Figure 41 : North American Market Shares of In Vitro Diagnostics Quality Controls, by Type of Manufacturer, 2023

Figure 42 : North American Market Shares of In Vitro Diagnostics Quality Controls, by Product and Service, 2023

Figure 43 : North American Market Shares of In Vitro Diagnostics Quality Control Products, by Type of Product, 2023

Figure 44 : North American Market Shares of In Vitro Diagnostics Quality Controls, by End User, 2023

Figure 45 : North American Market Shares of In Vitro Diagnostics Quality Controls, by Country, 2023

Figure 46 : European Market Shares of In Vitro Diagnostics Quality Controls, by Test Type, 2023

Figure 47 : European Market Shares of In Vitro Diagnostics Quality Controls, by Type of Manufacturer, 2023

Figure 48 : European Market Shares of In Vitro Diagnostics Quality Controls, by Product and Service, 2023

Figure 49 : European Market Shares of In Vitro Diagnostics Quality Control Products, by Type of Product, 2023

Figure 50 : European Market Shares of In Vitro Diagnostics Quality Controls, by End User, 2023

Figure 51 : European Market Shares of In Vitro Diagnostics Quality Controls, by Country, 2023

Figure 52 : Asia-Pacific Market Shares of In Vitro Diagnostics Quality Controls, by Test Type, 2023

Figure 53 : Asia-Pacific Market Shares of In Vitro Diagnostics Quality Controls, by Type of Manufacturer, 2023

Figure 54 : Asia-Pacific Market Shares of In Vitro Diagnostics Quality Controls, by Product and Service, 2023

Figure 55 : Asia-Pacific Market Shares of In Vitro Diagnostics Quality Control Products, by Type of Product, 2023

Figure 56 : Asia-Pacific Market Shares of In Vitro Diagnostics Quality Controls, by End User, 2023

Figure 57 : Asia-Pacific Market Shares of In Vitro Diagnostics Quality Controls, by Country, 2023

Figure 58 : Rest of World Market Shares of In Vitro Diagnostics Quality Controls, by Test Type, 2023

Figure 59 : Rest of World Market Shares of In Vitro Diagnostic Quality Controls, by Type of Manufacturer, 2023

Figure 60 : Rest of World Market Shares of In Vitro Diagnostics Quality Controls, by Product and Service, 2023

Figure 61 : Rest of World Market Shares of In Vitro Diagnostics Quality Control Products, by Type of Product, 2023

Figure 62 : Rest of World Market Shares of In Vitro Diagnostics Quality Controls, by End User, 2023

Figure 63 : Rest of the World Market Shares of In Vitro Diagnostics Quality Controls, by Country/Sub-Region, 2023

Figure 64 : Global Market Dynamics of Point-of-Care Diagnostics

Figure 65 : Malaria-Endemic Countries, 2022

Figure 66 : Top 10 Common Chronic Conditions in Adults 65+, U.S., 2024

Figure 67 : Annual Investment in STI Research Needs of People in Low- and Middle-Income Countries, 2018–2022

Figure 68 : Global Market Shares of Point-of-Care Diagnostics, by Test Type, 2023

Figure 69 : Share of New Cancer Cases Globally, by Region, 2022

Figure 70 : Share of Cancer Mortality Cases Globally, by Region, 2022

Figure 71 : Global Market Shares of Point-of-Care Diagnostics, by Product, 2023

Figure 72 : Global Market Shares of Point-of-Care Diagnostics, by End User, 2023

Figure 73 : COVID-19 Diagnostic Possibilities, Sampling, and Turnaround Time

Figure 74 : Global Market Shares of Point-of-Care Diagnostics, by Region, 2023

Figure 75 : North American Market Shares in Point-of-Care Diagnostics, by Country, 2023

Figure 76 : Limitations of Using POC Devices in India

Figure 77 : Global Market Shares of Polymerase Chain Reaction for Point-of-Care Diagnostics, by Product Type, 2023

Figure 78 : Polymerase Chain Reaction for Point of Care Diagnostics: Market Dynamics

Figure 79 : Emerging Trends and Technologies in PCR for POC Diagnostics

Figure 80 : Global Market Shares of Rare Disease Diagnostics, by Disease Class, 2023

Figure 81 : Market Dynamics of Rare Disease Diagnostics

Figure 82 : FDA Approval for Orphan Drugs, 2020–2023

Figure 83 : Cost Per Genome, November 2017–May 2022

Figure 84 : Phase-Out Plan of FDA’s Enforcement Discretion Approach

Figure 85 : Global Market Shares of Rare Disease Diagnostics, by Analysis Platform, 2023

Figure 86 : Global Market Shares of Rare Disease Diagnostics, by Analysis Target, 2023

Figure 87 : Global Market Shares of Rare Disease Diagnostics, by Disease Class, 2023

Figure 88 : Global Market Shares of Rare Disease Diagnostics, by Test Purpose, 2023

Figure 89 : Global Market for Rare Disease Diagnostics, by Region, 2021–2029

Figure 90 : Global Market Shares of Rare Disease Diagnostics, by Region, 2023

Figure 91 : NIH Funding for Rare Diseases, 2018–2025E

Figure 92 : North American Market Shares of Rare Disease Diagnostics, by Country, 2023

Figure 93 : European Market Shares of Rare Disease Diagnostics, by Country, 2023

Figure 94 : Asia-Pacific Market Shares of Rare Disease Diagnostics, by Country, 2023

BCC Research（BCCリサーチ）はライフサイエンス、センサ、マテリアル、環境、商取引関連市場を中心とした広範な市場調査レポートを出版する米国の調査会社です。

ライセンス別価格表

2024年11月より価格構成が大幅に変更になりました。最新の価格についてはお問合せください。

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

新価格表

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

旧価格表

旧ライセンスタイプ1

旧ライセンスタイプ2

ご購入に関するご案内

価格・納期について

• 価格
• ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • 2-5ライセンス
    • 同一企業内5名までレポートファイルのご利用が可能です。
  • サイトライセンス
    • 同一企業同住所内でレポートファイルのご利用が可能です。
  • エンタープライズライセンス
    • 同一企業内人数無制限でレポートファイルのご利用が可能です。
• 納品形態
  • Eメール
• 納期
  • ご注文後3営業日以内

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

BCC Researchが出版する調査レポートのサンプルページのご依頼、見積り、ご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• がん免疫療法の技術と世界市場 2025-04-17
• 再生可能エネルギーの技術と世界市場 2025-04-17
• 木材・プラスチック複合材の技術と世界市場 2025-04-17
• 先端材料の調査レビュー　2024年 2025-04-16
• コールドチェーンの地域別市場分析：中東＆北アフリカ 2025-04-16

BCC Research  出版レポート一覧